Orichem Drugs & Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 29-05-2024
- Paid Up Capital ₹ 9.00 M
as on 29-05-2024
- Company Age 38 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 5.00 M
as on 29-05-2024
- Revenue -9.94%
(FY 2022)
- Profit -67.48%
(FY 2022)
- Ebitda -42.68%
(FY 2022)
- Net Worth 17.52%
(FY 2022)
- Total Assets 16.12%
(FY 2022)
About Orichem Drugs & Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 9.00 M.
The company has closed loans amounting to ₹5.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Manjulata Jha, Anil Jha, Navin Jha, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232MP1986PTC003399
- Company No.
003399
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 May 1986
- Date of AGM
20 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Orichem Drugs & Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Navin Jha  | Managing Director | 08-Oct-2005 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Manjulata Jha | Whole-Time Director | 01-Jul-2000 | Current |
| Anil Jha | Whole-Time Director | 08-Oct-2005 | Current |
| Umesh Jha | Whole-Time Director | 07-Oct-2002 | Current |
Financial Performance and Corporate Structure Insights of Orichem Drugs & Pharmaceuticals.
Orichem Drugs & Pharmaceuticals Pvt. Ltd., for the financial year ended 2022, experienced Minor drop in revenue, with a 9.94% decrease. The company also saw a substantial fall in profitability, with a 67.48% decrease in profit. The company's net worth Soared by an impressive increase of 17.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Orichem Drugs & Pharmaceuticals?
In 2021, Orichem Drugs & Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Chandrashree Laboratories & Farm Products Pvt LtdActive 38 years 3 monthsManjulata Jha and Umesh Jha are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
H.D.F.C. Creation Date: 25 Feb 2004 | ₹5.00 M | Satisfied |
How Many Employees Work at Orichem Drugs & Pharmaceuticals?
Unlock and access historical data on people associated with Orichem Drugs & Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Orichem Drugs & Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Orichem Drugs & Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
